These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15501061)

  • 1. Tetrahydroisoquinoline derivatives as melatonin MT2 receptor antagonists.
    Karageorge GN; Bertenshaw S; Iben L; Xu C; Sarbin N; Gentile A; Dubowchik GM
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5881-4. PubMed ID: 15501061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
    Bedini A; Spadoni G; Gatti G; Lucarini S; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Scaglione F
    J Med Chem; 2006 Dec; 49(25):7393-403. PubMed ID: 17149869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening assay for new ligands at human melatonin receptors.
    Yan JH; Su HR; Boutin JA; Renard MP; Wang MW
    Acta Pharmacol Sin; 2008 Dec; 29(12):1515-21. PubMed ID: 19026172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands.
    Hu Y; Ho MK; Chan KH; New DC; Wong YH
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2582-5. PubMed ID: 20227878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers.
    Ayoub MA; Levoye A; Delagrange P; Jockers R
    Mol Pharmacol; 2004 Aug; 66(2):312-21. PubMed ID: 15266022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists.
    Spadoni G; Bedini A; Diamantini G; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Caronno A; Fraschini F
    ChemMedChem; 2007 Dec; 2(12):1741-9. PubMed ID: 17907131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
    Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
    Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
    Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.
    Durieux S; Chanu A; Bochu C; Audinot V; Coumailleau S; Boutin JA; Delagrange P; Caignard DH; Bennejean C; Renard P; Lesieur D; Berthelot P; Yous S
    Bioorg Med Chem; 2009 Apr; 17(8):2963-74. PubMed ID: 19329323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards the development of mixed MT(1)-agonist/MT(2)-antagonist melatonin receptor ligands.
    Spadoni G; Bedini A; Guidi T; Tarzia G; Lucini V; Pannacci M; Fraschini F
    ChemMedChem; 2006 Oct; 1(10):1099-105. PubMed ID: 16955531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
    Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
    J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.
    Poissonnier-Durieux S; Ettaoussi M; Pérès B; Boutin JA; Audinot V; Bennejean C; Delagrange P; Caignard DH; Renard P; Berthelot P; Lesieur D; Yous S
    Bioorg Med Chem; 2008 Sep; 16(18):8339-48. PubMed ID: 18778943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies leading to MT2 selective melatonin receptor antagonists.
    Spadoni G; Bedini A; Piersanti G; Mor M; Rivara S; Tarzia G
    Adv Exp Med Biol; 2003; 527():577-85. PubMed ID: 15206776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding.
    Mazna P; Obsilova V; Jelinkova I; Balik A; Berka K; Sovova Z; Ettrich R; Svoboda P; Obsil T; Teisinger J
    J Neurochem; 2004 Nov; 91(4):836-42. PubMed ID: 15525337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in melatonin receptor ligands.
    Zlotos DP
    Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
    Tsotinis A; Vlachou M; Papahatjis DP; Calogeropoulou T; Nikas SP; Garratt PJ; Piccio V; Vonhoff S; Davidson K; Teh MT; Sugden D
    J Med Chem; 2006 Jun; 49(12):3509-19. PubMed ID: 16759094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Substituted anilides as selective melatonin MT2 receptor agonists.
    Epperson JR; Deskus JA; Gentile AJ; Iben LG; Ryan E; Sarbin NS
    Bioorg Med Chem Lett; 2004 Feb; 14(4):1023-6. PubMed ID: 15013015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.